MergerLinks’ Post

Biolexis Therapeutics, an AI-driven drug discovery company, has secured $10 million in Series A funding, paving the way for advancements in metabolic drug development. Their focus is broad, targeting age-related conditions and exploring potential applications in human longevity. With an impressive 40 active programs in discovery and ten pipeline programs in the IND-enabling stages of development, Biolexis stands at the frontier of addressing healthcare challenges. How do you view the role of AI in accelerating drug discovery?   #longevity #metabolicdrugprogram  

Fanconi Anemia Pipeline Forecast 2024: FDA Approvals, Therapies, and Leading Companies | Foresee Pharma, Rocket Pharma, John Diaz, Novartis, Sierra Oncology: (Las Vegas, Nevada, United States) As per DelveInsight’s assessment, globally, Fanconi Anemia pipeline constitutes key companies continuously working towards developing Fanconi Anemia treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight. The … Continue reading → #Business #HealthMedicine #MarketingSales #PharmaceuticalsBiotech

We are excited to announce Deciduous Therapeutics as a Tier 3 Sponsor of the 11th Aging Research & Drug Discovery Meeting. Deciduous Therapeutics is a San Francisco based, venture backed start-up focused on harnessing the immune system to treat diseases of aging. Specifically, the company is focused on restoring natural killer t-cell function to systemically ablate pathological senescent cells. The company had demonstrated that a single dose of its proprietary NKT agonist is able to selectively remove senescent cells, resulting in disease resolution in both fibrosis and metabolic disease models. #ARDD2024 will feature a dynamic mix of academic institutions, clinicians, industry leaders, and pharmaceutical companies, fostering rich dialogues and unveiling new research in the field of aging. Mark your calendars for August 26-30, 2024 and register now at agingpharma.org https://lnkd.in/ggNnNTeh #ARDD2024 #DrugDiscovery #AgingResearch

Contineum Therapeutics, a Phase 1 biotech developing small molecule therapies for NI&I indications, filed on Friday with the SEC to raise up to $150 million in an initial public offering. Contineum Therapeutics is focused on discovering and developing novel, oral small molecule therapies for the treatment of neuroscience, inflammation, and immunology (NI&I) indications with high unmet need. Its wholly-owned lead asset, PIPE-791, is a novel, brain penetrant, small molecule inhibitor in development for idiopathic pulmonary fibrosis (IPF) and progressive multiple sclerosis (Progressive MS). The company has completed a Phase 1 trial of PIPE-791 in healthy volunteers in both indications, and it plans to submit a Clinical Trial Authorization to the Medicines and Healthcare products Regulatory Agency to commence a Phase 1b open-label trial in 2024. Contineum is collaborating with Johnson & Johnson on its second candidate, PIPE-307, which has entered a Phase 2 trial in relapse remitting MS. #biotech #biotechnology #capitalmarket #capitalraise #ipos #initialpublicoffering #therapeutics #moleculetherapies #sec #healthcare

Vertex Pharmaceuticals will Buy Alpine Immune Sciences for $4.9B in Another Big Seattle Biotech Deal https://lnkd.in/grf4EP4y Boston-based biotech company Vertex Pharmaceuticals agreed to acquire Seattle-based Alpine Immune Sciences for $65 per share, totaling about $4.9 billion in cash, a 38% premium over Alpine’s closing price on Wednesday afternoon. The premium would have been higher, around 67%, based on Alpine’s closing price on Tuesday. However, the company’s stock jumped 21% in regular trading Wednesday after Bloomberg News reported it was considering a sale. Alpine develops immunotherapies to address cancer, kidney disease, and other serious autoimmune and inflammatory conditions by engineering proteins that influence the body’s immune response. The post Vertex Pharmaceuticals will Buy Alpine Immune Sciences for $4.9B in Another Big Seattle Biotech Deal appeared first on Life Science Washington . Click here to view original post Click Here to Publish/Feature Your Company or Product News with Biotech Networks

#Cellular_Immunotherapy Market | Latest Trend, Growth & Forecast 2023-2032. >> https://lnkd.in/dARkZyDe This robust #growth of the #cellular #immunotherapy #market is driven by several factors such as increasing acceptance of immunotherapy over conventional therapies, growing emergence of #biosimilars, increasing #demand for #monoclonal #antibodies (mAbs), and rising prevalence of cancer among a growing population. Bristol-Myers Squibb Pharma Company Novartis Gilead Sciences. F. Hoffmann-La Roche Ltd Merck KGaA, Darmstadt, Germany GSK AstraZeneca Pfizer Johnson & Johnson Celyad Oncology Adicet Bio, Inc Dendreon Pharmaceuticals Inc #Cellular_Immunotherapy #biotechnology #business_opportunities #marketanalysis #marketresearch #opportunities #business #future #cellular #immunotherapy

⏭ Here are some recent biopharma news stories ¹ ² ³ ⁴: Ø Bristol Myers’ leukemia drug Sprycel faces competition from generic versions in the US market Ø The US FDA rejected Novo Nordisk’s application for a new insulin product Ø The US Federal Trade Commission is suing CVS Caremark, Express Scripts, and Optum Rx over their drug price practices Ø AbbVie’s Humira lost more market share to biosimilars after being removed from CVS Caremark’s formularies Ø Pfizer and Evotec are collaborating on early discovery research for metabolic and infectious disease therapeutics Ø Roche recalled Susvimo’s ocular implant, insertion tool, and initial fill kit due to unsatisfactory test results Ø Novo Nordisk is investing $4.1 billion in a new fill/finish manufacturing facility in North Carolina. Source:1 https://lnkd.in/g7XdPHEf 2 https://lnkd.in/gQc9nbYQ 3,4 https://lnkd.in/gZYKFhs6 https://lnkd.in/gDgEyQ-t

9 Biotech companies to watch in 2024 As 2024 unfolds, the biotechnology industry is brimming with potential, spearheading scientific innovation. This year is particularly exciting as a diverse range of biotech companies are poised to break new ground to tackle global challenges. Here are nine biotech companies we will follow in 2024. #biotech #pharma #businessdevelopment #licensing Aiolos Bio Capstan Therapeutics Carisma Therapeutics Cellarity Kriya Therapeutics, Inc. Maze Therapeutics Quotient Sciences OrsoBio https://lnkd.in/dYN9nf8e

BioPharmaDive have released a new report looking at the recent upswing in Biotech M&As. We all know that 2023 was a tough year for many biotechs. What is interesting however is that 2023 was also a big years for deals and M&As, especially for large cap deals. Listed are just some I could find, all $1bn and above. Even with all the big obesity hype (even bigger with the recent Catalent proposed take-over from Novo) - it was ADCs, Oncology and Neuroscience that actually attracted the biggest investments in 2023. BMS: Karuna Therapeutics for $14bn, RayzeBio for $4.1bn Abbvie: ImmunoGen, Inc. for $10.1bn, Cerevel Therapeutics for $8.7bn Lilly: PointBio, for $1.4bn, @Dice Therapeutics for $2.4bn Versanis Bio, $1.9bn Novo Nordisk KBP Biosciences for $1.3bn, Inversago Pharma for $1.1bn Pfizer Seagen for $43 bn

[Clinical Trials] Applied Therapeutics, Inc. reports phase 3 trial results of AT-007 in SORD deficiency showing reduced sorbitol levels and improved patient-reported outcomes https://lnkd.in/gg96b8w6 CSL Behring B.V. and ABIONYX Pharma's CSL112 fails to meet endpoint in phase 3 AMI trial https://lnkd.in/geXfwXKK Tonix Pharmaceuticals' phase 3 trial of Tonmya achieves primary endpoint in fibromyalgia with reductions in pain and improvements in sleep and fatigue https://lnkd.in/ggYnsuyc Corcept Therapeutics' phase 4 trial of Korlym identifies hypercortisolism in 24% of Cushing's syndrome patients https://lnkd.in/gcXUpvw6 [Deals] Kelonia Therapeutics enters strategic collaboration with and Xyphos Biosciences for oncology CAR-T therapy candidate for $875 M https://lnkd.in/gF3YSD4Q ReCode Therapeutics and Intellia Therapeutics, Inc. sign strategic collaboration to advance gene editing therapy candidate for cystic fibrosis https://lnkd.in/gVrnsA94 Harrow and Apotex Inc. sign license agreement granting Canadian rights to market VERKAZIA for Vernal Keratoconjunctivitis and 4 more ophthalmic drugs https://lnkd.in/gKyvwvgk